Medical Affairs Reputations: Cancer Pain (US) 2017

Wednesday, November 8, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 7, 2017 /PRNewswire/ -- Disappointing scores show that medical affairs teams need to up their gameThe medical

oncologists we surveyed say that medical affairs teams for cancer pain drugs turned in a lacklustre performance in the past 6 months. Their ratings on individual services barely crept into positive territory, and even though they're contacting doctors
a little too often, they're failing to deliver the information doctors need. In other words, there's plenty of room for improvement, and a motivated team can seize the opportunity to leap ahead of the competition. Read the full report: out what your team gets right, and where it's going wrong in Medical Affairs Reputations: Cancer Pain (US). Comparing 6 major cancer pain treatments from Endo Pharmaceuticals, Insys Therapeutics, Mallinckrodt, Purdue Pharma, and Teva, this report reveals: How doctors rate your team overall, and on 12 key medical affairs services.Which medical affairs services are most important, and what you can do to improve them.How, and how often doctors want to meet with your team.That's actionable information you can use to turn your team into one that doctors rely on. Top Takeaways

  • Scores are so-so: Performance and satisfaction ratings for individual medical affairs services are neutral to somewhat positive. 
  • No one brand stands out: Most teams earned similar overall quality scores. Performance and satisfaction ratings are also similar. 
  • Specific improvements needed: 5 of the surveyed teams need to improve between 1 and 3 specific services. 
  • Over 40% of doctors say teams could do a better job of providing information: They identified 4 ways teams can improve, and highlighted 3 specific types of information they want more of. 
  • Teams may be over-communicating: Doctors tend to want to hear from teams less often than teams are contacting them. 
  • Time to pick up the pace: Only one team interacted with more than 65% of the surveyed doctors in the past 6 months. 

Insight into Medical Affairs Teams for These Cancer Pain TreatmentsActiq (fentanyl transmucosal; Teva) Exalgo (hydromorphone CR; Mallinckrodt) Opana (oxymorphone IR; Endo Pharmaceuticals) Opana ER (oxymorphone ER; Endo Pharmaceuticals) OxyContin (oxycodone CII; Purdue Pharma) Subsys (fentanyl sublingual; Insys Therapeutics) An Expert-designed Competitive View of Your Medical Affairs TeamsDeveloped with the help of medical affairs specialists, this report gives you an in-depth comparison of 6 medical affairs teams—answering important questions like: 

  • What do doctors need?
  • How, and how often are doctors using your medical affairs team? 
  • What services do they consider most important? 
  • How often should you contact them? What channels are best? 

Does your medical affairs team deliver?How memorable are your team's interactions with doctors? How do doctors rank your team for performance and satisfaction in 12 key areas? How does your team compare to the competition—in each area, and overall? What needs improvement?Are you delivering the services that are most important to doctors? Where do you need to improve? How can your team enhance its services? Based on Expert KnowledgeWe surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world. All respondents: Have been practicing for between 3 and 35 yearsSee at least 5 patients with cancer pain in a typical monthDevote at least 50% of their time to direct patient careHave interacted with at least one listed product's medical affairs team in the past 6 months. We conducted the survey between June 1st and 7th, 2017. 

Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001

View original content:

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store